Clinical trial endpoints

Friday, May 3, 2019: 5:30 PM-7:00 PM
Room: 710 (Palais des congres de Montreal)
5:30 PM
204.065
65 Initial Severity of Autism Symptoms Moderates the Effect of Intensity on Expressive Communication in Children with ASD
P. Yoder Z. Warren S. Rogers A. Estes G. Hellemann J. Munson
5:30 PM
204.066
66 The Effects of Pivotal Response Training on Reciprocal Vocal Contingency in Children with Autism Spectrum Disorder
P. Yoder J. McDaniel M. Crandall M. E. Millan C. Ardel G. W. Gengoux A. Y. Hardan
5:30 PM
204.067
67 Objective Measurement of Initiations to Peers Following Behavioral Social Skills Treatment
G. W. Gengoux J. Hopkins A. A. Ruiz M. E. Millan R. K. Schuck Y. Weng J. Long A. Y. Hardan
5:30 PM
204.068
68 The Sensory Domain As a Target for Treatment in ASD Clinical Trials: Electrophysiological and Behavioral Markers of Therapeutic Change
P. M. Siper T. Tavassoli A. Kolevzon
5:30 PM
204.069
69 Using fMRI to Identify Neural Mechanisms of Response to Cognitive Behavioral Therapy for Anxiety in ASD
D. G. Sukhodolsky K. Ibrahim C. Kalvin J. Eilbott K. A. Pelphrey
5:30 PM
204.070
70 Using the Boscc As Primary Outcome of the German A-FFIP Multicenter RCT
J. Kitzerow S. Kleber Z. Kim K. Teufel C. Freitag
5:30 PM
204.071
71 A Lifespan Approach to Patient-Reported Outcomes and Quality of Life for Autism Using Nih Promis®
L. Graham Holmes C. J. Zampella C. C. Clements B. B. Maddox J. McCleery J. Parish-Morris R. T. Schultz J. S. Miller
5:30 PM
204.072
72 Effects rTMS-Based Neuromodulation Dosage on Event-Related Potentials and Evoked and Induced Gamma Oscillations in Children with Autism Spectrum Disorder
M. Casanova E. M. Sokhadze E. V. Lamina E. L. Casanova D. P. Kelly
5:30 PM
204.073
73 Psychometric Properties of a Novel Vineland-II™ 2-Domain Composite Score to Assess Social Communication and Social Interaction in Autism Spectrum Disorder
G. Dawson T. Willgoss S. Le Scouiller L. Squassante K. Sanders J. W. Smith F. Bolognani R. L. Findling
5:30 PM
204.074
74 Significant Increase in Power in Clinical Trials with Use of the Newly Available Vineland-3 Growth Scale Values
C. Farmer A. Thurm J. S. Miller
5:30 PM
204.075
75 Vineland™-II Adaptive Behavior Scales for Autism Spectrum Disorder: An Electronic Version Is Conceptually Equivalent to the Standard Paper Version
T. Willgoss G. Deol-Bhullar R. Swinhoe J. W. Smith
5:30 PM
204.076
76 ‘Play As You Do at Home’: Using the Who Adapted Joint Engagement Rating Inventory (JERI) to Measure Caregiver-Child Interaction
E. Salomone M. Settanni F. Ferrara G. Foletti C. Servili K. Suma R. Bakeman L. B. Adamson
See more of: Clinical Trial Endpoints
<< Previous Panel | Next Panel >>